Lung Transplant Rejection – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Lung Transplant Rejection – Pipeline Review, H2 2017’, provides an overview of the Lung Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lung Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Lung Transplant Rejection

The report reviews pipeline therapeutics for Lung Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Lung Transplant Rejection therapeutics and enlists all their major and minor projects

The report assesses Lung Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Lung Transplant Rejection

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Lung Transplant Rejection

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Lung Transplant Rejection pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Apeptico Forschung und Entwicklung GmbH

Astellas Pharma Inc

Dompe Farmaceutici SpA

Kamada Ltd

MimeTech Srl

Novartis AG

Quark Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Lung Transplant Rejection - Overview 6

Lung Transplant Rejection - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 9

Lung Transplant Rejection - Therapeutics Assessment 10

Assessment by Target 10

Assessment by Mechanism of Action 12

Assessment by Route of Administration 14

Assessment by Molecule Type 16

Lung Transplant Rejection - Companies Involved in Therapeutics Development 18

Apeptico Forschung und Entwicklung GmbH 18

Astellas Pharma Inc 18

Dompe Farmaceutici SpA 18

Kamada Ltd 19

MimeTech Srl 19

Novartis AG 20

Quark Pharmaceuticals Inc 20

Lung Transplant Rejection - Drug Profiles 22

alpha-1 proteinase inhibitor (human) - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

FX-06 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

MT-8 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

QPI-1024 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

QPLI-1 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

R-554 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

R-801 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

reparixin - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

solnatide - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

tacrolimus - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

tiprelestat - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Zortress - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Lung Transplant Rejection - Dormant Projects 48

Lung Transplant Rejection - Product Development Milestones 49

Featured News & Press Releases 49

Oct 09, 2017: Quark Pharmaceuticals to Present Preclinical Efficacy Data on Inhaled siRNA Co-Developed with Biocon for Prevention of Primary Graft Dysfunction following Lung Transplantation at the 6th Annual RNAi China Conference 49

Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 49

Dec 09, 2015: Quark announces issue of U.S. patent for novel treatment of lung transplantation associated injury 51

Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 51

Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs 52

Apr 17, 2013: APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation 53

Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 53

Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria 54

Appendix 56

Methodology 56

Coverage 56

Secondary Research 56

Primary Research 56

Expert Panel Validation 56

Contact Us 56

Disclaimer 57

List of Tables

List of Tables

Number of Products under Development for Lung Transplant Rejection, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Products under Development by Companies, H2 2017 9

Number of Products by Stage and Target, H2 2017 11

Number of Products by Stage and Mechanism of Action, H2 2017 13

Number of Products by Stage and Route of Administration, H2 2017 15

Number of Products by Stage and Molecule Type, H2 2017 17

Lung Transplant Rejection – Pipeline by Apeptico Forschung und Entwicklung GmbH, H2 2017 18

Lung Transplant Rejection – Pipeline by Astellas Pharma Inc, H2 2017 18

Lung Transplant Rejection – Pipeline by Dompe Farmaceutici SpA, H2 2017 19

Lung Transplant Rejection – Pipeline by Kamada Ltd, H2 2017 19

Lung Transplant Rejection – Pipeline by MimeTech Srl, H2 2017 20

Lung Transplant Rejection – Pipeline by Novartis AG, H2 2017 20

Lung Transplant Rejection – Pipeline by Quark Pharmaceuticals Inc, H2 2017 21

Lung Transplant Rejection – Dormant Projects, H2 2017 48

List of Figures

List of Figures

Number of Products under Development for Lung Transplant Rejection, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products by Top 10 Targets, H2 2017 10

Number of Products by Stage and Top 10 Targets, H2 2017 10

Number of Products by Top 10 Mechanism of Actions, H2 2017 12

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 12

Number of Products by Routes of Administration, H2 2017 14

Number of Products by Stage and Routes of Administration, H2 2017 14

Number of Products by Molecule Types, H2 2017 16

Number of Products by Stage and Molecule Types, H2 2017 16

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports